Back

A strategy of eculizumab treatment withdrawal with disease monitoring is cost-effective compared to lifelong treatment for eligible atypical haemolytic uraemic syndrome patients: an economic evaluation of the SETS aHUS trial.

2025-07-15 health economics Title + abstract only
View on medRxiv
Show abstract

Background and hypothesisAtypical haemolytic uraemic syndrome (aHUS) is a rare condition caused by compliment dysregulation. Eculizumab is an effective treatment for patients with aHUS, yet a lifelong treatment strategy is costly for health services and is of uncertain additional benefit to patients. This economic evaluation was conducted as part of stopping eculizumab treatment safely in aHUS (SETS aHUS) trial and assessed the cost-effectiveness of a lifelong delivery of eculizumab strategy com...

Predicted journal destinations

1
PLOS ONE
1737 training papers
Top 43% 16.6%
2
BMC Medicine
155 training papers
Top 2% 5.6%
3
Scientific Reports
701 training papers
Top 51% 5.6%
4
PLOS Medicine
95 training papers
Top 0.9% 4.7%
5
Clinical Infectious Diseases
219 training papers
Top 8% 4.7%
6
BMJ Open
553 training papers
Top 35% 4.7%
7
Infectious Diseases and Therapy
18 training papers
#1 3.6%
8
Proceedings of the National Academy of Sciences
100 training papers
Top 4% 2.9%
9
Journal of Clinical Medicine
77 training papers
Top 10% 1.8%
10
Genetics in Medicine
57 training papers
Top 6% 1.8%
11
Nature Communications
483 training papers
Top 40% 1.8%
12
eClinicalMedicine
55 training papers
Top 1% 1.4%
13
Journal of Medical Virology
95 training papers
Top 8% 1.4%
14
Annals of the Rheumatic Diseases
23 training papers
Top 0.9% 1.4%
15
The Lancet
16 training papers
#1 1.4%
16
Clinical Microbiology and Infection
54 training papers
Top 4% 1.4%
17
PLOS Neglected Tropical Diseases
166 training papers
Top 13% 1.4%
18
Viruses
79 training papers
Top 5% 1.4%
19
Microorganisms
21 training papers
#1 1.3%
20
The Journal of Infectious Diseases
137 training papers
Top 12% 1.3%
21
BMC Health Services Research
43 training papers
Top 4% 1.1%
22
JAMA Network Open
125 training papers
Top 21% 1.1%
23
Vaccine
140 training papers
Top 8% 0.9%
24
Frontiers in Immunology
140 training papers
Top 12% 0.9%
25
eLife
262 training papers
Top 48% 0.9%
26
Open Forum Infectious Diseases
124 training papers
Top 17% 0.7%
27
Journal of Clinical Investigation
50 training papers
Top 7% 0.7%
28
BMJ Global Health
95 training papers
Top 21% 0.7%
29
Frontiers in Medicine
99 training papers
Top 26% 0.7%